FDA Clearance Paves Way for Quantum BioPharma's Phase 2 Trial of Lucid-MS in Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) has reached a critical regulatory milestone with the U.S. Food and Drug Administration's clearance of its Investigational New Drug application for Lucid-MS, the company's patented new chemical entity for multiple sclerosis. The clearance, announced in a recent NetworkNewsAudio press release, enables Quantum to initiate a Phase 2 clinical trial, a significant step for a micro-cap biotech company.

The approximately 15,000-page IND submission included comprehensive pharmacology, toxicology, and manufacturing data, demonstrating the company's readiness to advance Lucid-MS into human testing. With FDA clearance, Quantum can now proceed directly to a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the drug in people with multiple sclerosis. This trial design is considered the gold standard for assessing efficacy and safety, and its initiation marks a pivotal moment for the company and for patients.

Lucid-MS has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis. Myelin is the protective sheath around nerve fibers, and its damage leads to the neurological symptoms associated with MS, such as weakness, numbness, and vision problems. Currently available treatments primarily modulate the immune system but do not directly repair myelin. If Lucid-MS can replicate its preclinical results in humans, it could represent a paradigm shift in MS therapy by addressing the disease's root cause rather than just managing symptoms.

The implications of this announcement extend beyond Quantum BioPharma. For the approximately 2.8 million people worldwide living with MS, a therapy that reverses myelin damage could offer hope for recovery of lost function and slowing of disease progression. The successful development of such a treatment would also validate Quantum's approach and potentially open doors to applying similar mechanisms to other neurodegenerative conditions. The company's pipeline includes assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, suggesting broader potential applications.

Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. The company also invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. For more information, visit the full press release and the company's newsroom.

The FDA's clearance of the IND is a de-risking event for Quantum BioPharma, as it confirms that the company's preclinical data and manufacturing processes meet regulatory standards for human testing. However, the Phase 2 trial will be the true test of Lucid-MS's efficacy. Success would not only boost Quantum's valuation but also attract partnership or acquisition interest from larger pharmaceutical companies. Conversely, failure would be a significant setback. The trial's progress will be closely watched by investors and the MS community alike.